06/02/2024

Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care

Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation sequencing assays.

ADCs are an expanding class of therapies designed to target and kill tumor cells while sparing healthy cells. These very targeted therapies are available to patients with specific indications, including HER2 and FOLR1 expressing tumors. Tempus is now offering these two IHC tests, which are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician’s discretion. The new offerings further expand Tempus’ comprehensive portfolio of testing solutions that is designed to help physicians maximize and optimize treatment options for each of their patients. 

The portfolio expansion aligns well with the most recent approval by the Food & Drug Administration (FDA) of trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. In addition, reflex to ERBB2 FISH is available for breast and gastric (including colorectal) cancer patients. This approval highlights the importance of comprehensive HER2 testing in guiding targeted therapy decisions. FOLR1 testing is recommended for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.1

“Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “These are the kind of critical tools that we are arming physicians with as new, targeted therapies are made available for patients.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

 1 NCCN Clinical Practice Guidelines in Oncology. Ovarian. Version 1.2024.

Related Content

View more
  • post image
    02/13/2025

    AI & ML in action: Real-time advances in precision medicine

    Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential.

    Watch replay
  • post image
    01/27/2025

    Addressing health disparities at a large academic medical center: AI-driven cardiac care for aortic stenosis and mitral regurgitation

    Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked.

    Read more
  • post image
    12/05/2024

    Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies

    Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. Discover the significant developments that are helping to shape clinical trials and improving patient outcomes in IO and hear perspectives from industry experts on the potential of emerging therapies.

    Watch replay